Live Breaking News & Updates on Phasei Clinical Trials Program|Page 3

Credit: MD Anderson Cancer Center
HOUSTON The glutaminase (GLS1) inhibitor IACS-6274, discovered and developed by The University of Texas MD Anderson Cancer Center s Therapeutics Discovery division, appears to be well-tolerated with successful target inhibition and early signs of anti-tumor activity in a biomarker-driven Phase I trial. Interim results of the study will be presented at the 2021 American Society for Clinical Oncology (ASCO) Annual Meeting on June 4.
On the trial, 17 of 20 evaluable patients achieved a best response of stable disease, with a disease control rate of 60% at 12 weeks. Six patients with biomarker-defined advanced cancers had meaningful durable disease stabilization for greater than six months, with evidence of tumor shrinkage. ....

United States , Timothya Yap , Md Anderson Phasei Clinical Trials Program , Institute For Applied Cancer Science , Translational Research To Advance Therapeutics , American Society For Clinical Oncology , Department Of Investigational Cancer Therapeutics , Cancer Center , Therapeutics Discovery , Clinical Oncology , Annual Meeting , Investigational Cancer Therapeutics , Applied Cancer Science , Translational Research , Advance Therapeutics , Phasei Clinical Trials Program , Investigational Cancer , Cell Biology , Molecular Biology , Medicine Health , ஒன்றுபட்டது மாநிலங்களில் , நிறுவனம் க்கு பயன்படுத்தப்பட்டது புற்றுநோய் அறிவியல் , அமெரிக்கன் சமூகம் க்கு மருத்துவ புற்றுநோயியல் , புற்றுநோய் மையம் , சிகிச்சை கண்டுபிடிப்பு , மருத்துவ புற்றுநோயியல் ,